Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Prucalopride Succinate

FDA-approved product (tablet, oral), marketed as Motegrity, Prucalopride Succinate.

Registered studies
7
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Prucalopride Succinate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Constipation
  • Constipation disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other drugs for constipation
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA59.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli48.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae33.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis43.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

7registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Prucalopride Succinate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Prucalopride Succinate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • The Effect of Prucalopride Succinate on Gastrointestinal Motility After Laparoscopic Gastrectomy : Prospective Double Blind Case-control Study

    NCT05966246 · start 2022-01-25

    Registered record
    Registry ID
    NCT05966246
    Conditions
    Gastric Cancer
    Interventions
    Arm I : Experimental (Prucalopride succinate group); Arm II : Control (Mosapride citrate group)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-01-25
    Completion
    2023-06-30
    Enrolment
    106

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastric Cancer
    InterventionArm I : Experimental (Prucalopride succinate group); Arm II : Control (Mosapride citrate group)
    PhaseNot applicable
    Registry statusCompleted

  • Prucalopride for Postoperative Ileus in Patients Undergoing Robot-assisted Laparoscopic Radical Cystectomy

    NCT05001763 · start 2021-09-01

    Registered record
    Registry ID
    NCT05001763
    Conditions
    Postoperative Ileus; Bladder Cancer
    Interventions
    Prucalopride; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2021-09-01
    Completion
    2023-10-01
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Ileus; Bladder Cancer
    InterventionPrucalopride; Placebo
    PhasePhase 2
    Registry statusUnknown

  • A Study of Prucalopride For Functional Constipation in Children and Teenagers

    NCT04759833 · start 2021-07-13

    Registered record
    Registry ID
    NCT04759833
    Conditions
    Constipation
    Interventions
    Prucalopride; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2021-07-13
    Completion
    2023-11-13
    Enrolment
    175

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionConstipation
    InterventionPrucalopride; Placebo
    PhasePhase 3
    Registry statusTerminated

  • Effect Comparison of Electro-acupuncture and Prucalopride for Severe Chronic Constipation: a Randomized Controlled Trial

    NCT02047045 · start 2014-04

    Registered record
    Registry ID
    NCT02047045
    Conditions
    Constipation
    Interventions
    acupuncture; Prucalopride
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2014-04
    Completion
    2017-05
    Enrolment
    560

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionConstipation
    Interventionacupuncture; Prucalopride
    PhaseNot applicable
    Registry statusCompleted

  • Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of YH12852 After Oral Administration in Healthy Male Subjects

    NCT01870674 · start 2013-08

    Registered record
    Registry ID
    NCT01870674
    Conditions
    Healthy
    Interventions
    YH12852; Prucalopride; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-08
    Completion
    2015-04
    Enrolment
    127

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionYH12852; Prucalopride; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled Prucalopride Succinate in Volunteers

    NCT01807000 · start 2013-03-18

    Registered record
    Registry ID
    NCT01807000
    Conditions
    Healthy
    Interventions
    Radiolabeled Prucalopride Succinate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-03-18
    Completion
    2013-04-28
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionRadiolabeled Prucalopride Succinate
    PhasePhase 1
    Registry statusCompleted

  • Effect of PEG, Bisacodyl and Prucalopride on Colonic Motility in Healthy Subjects

    NCT03279341 · start 2012-12-03

    Registered record
    Registry ID
    NCT03279341
    Conditions
    Chronic Constipation
    Interventions
    polyethylene glycol; Bisacodyl; Prucalopride
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-12-03
    Completion
    2016-03
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Constipation
    Interventionpolyethylene glycol; Bisacodyl; Prucalopride
    PhasePhase 4
    Registry statusCompleted